Background Endovascular therapy (EVT) is standard treatment for large vessel occlusion in patients with a National Institutes ...

In patients with AF and COVID-19 who receive DOAC, 30-day mortality risk is similar for nirmatrelvir/ritonavir and RdRp inhibitors.

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

A new study finds that a significant portion of older adults with mild cognitive impairment or dementia develop new ...

John Lock was born with his heart on the opposite side of his chest. It was never an issue until he developed atrial fibrillation — a common heart condition that put his life at risk and created a ...

CHARLESTON, S.C. (WCSC) — Both doctors and patients say being extra aware of how a heart is beating could save lives. The Medical University of South Carolina’s Chief of Cardiac Electrophysiology and ...

NEW YORK (AP) — Daniel Moore was about 30 the first time it happened. At the end of a long, hot, stressful day, he chugged an ice-cold glass of milk. “It felt like a bunny rabbit trying to jump out of ...

Pulse Biosciences PLSE recently announced late-breaking data from its first-in-human feasibility study of the nPulse Cardiac Catheter System using Nanosecond Pulsed Field Ablation energy. Presented at ...

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months “These 6- and 12-month data demonstrate a strong safety profile with highly effective and durable PVI ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking ...

“These 6- and 12-month data demonstrate a strong safety profile with highly effective and durable PVI achieved with the nPulse Cardiac Catheter Ablation System, suggesting that this system has the ...